Psychiatric Disorders in Children and Adolescents
• 10-15% of children in USA are affected by significant psychiatric illness, 21% in those 9-17 years of age • Only 20% of those affected receive treatment in a given year and 14.2% of youth reported psychotropic medication use • The majority if youth prescribed medications had mental disorder with severe consequences, functional impairment, suicidality or associated behavioral or emotional difficulties
Child & Adolescent Psychopharmacology
• National Center for Health Statistics reports that 7.5% of U.S. children between ages 6 and 17 were taking medication for "emotional or behavioral difficulties" in 2011-2012 • The CDC reports a five-fold increase in the number of children under 18 on psychostimulants from 1988-1994 to 2007-2010 • The same report estimates that 1.3 percent of children are on antidepressants • The rate of antipsychotic prescriptions for children has increased six-fold over this same period o Methylphenidate -----------ADHD ≥ 6 years o Dexmethylphenidate------ADHD ≥ 6 years o Amphetamines--------------ADHD ≥ 3 years o Lisdexampfetamine-------ADHD ≥ 6 years 
SNRI and alpha-2-agonist o Atomoxetine------------------ADHD ≥ 6 years o Clonidine----------------------ADHD ≥ 6 years o Guanfacine-------------------ADHD ≥ 6 years

FDA Approved Psychotropic Medications for Children and Adolescents
• Antidepressants o Sertraline----------------OCD ≥ 6 years o Escitalopram-----------MDD ≥ 12 years o Fluvoxamine------------OCD ≥ 7 years o Clomipramine----------OCD ≥ 10 years o Fluoxetine---------------MDD ≥ 8 years and OCD ≥ 7 years
Pharmacokinetics in Children
• How the drug is absorbed, how it's transformed in the liver, how it's distributed in the body, how it's excreted by the kidneys. Determines blood level of drug and used to determine dosage
• Kids are not "little adults" and relative mass of liver and kidney tissue is greater than in adults when adjusted for body weight
• Children have greater drug extraction during 1 st pass through liver, lower bioavailability, faster metabolism and elimination
Pharmacokinetics
• Due to faster elimination, drug plasma half-life can be shorter in children and steady-state may be reached sooner
• More frequent dosing may be needed to maintain consistent therapeutic levels
• Drug distribution usually reaches adult levels by middle or last adolescence
Pharmacokinetics in Children
• Most important CYP 450 enzymes in pediatric psychopharmacology are CYP3A4 and CYP2D6 which are involved in the metabolism of most psychotropics used in this population
• CYP3A4, CYP2D6 reaches adult activity levels by 2 weeks of life
• Genetic polymorphism has been identified for multiple CYP genes including CYP2D6 and 3A4
• Poor metabolizers may end-up with higher drug concentrations in plasma and other body fluids
Pharmacodynamics
• The biochemical and physiological effects of drugs on the body • Developmental stage influences the response to a number of psychotropics • Receptor density tends to peak in preschool years and gradually declines toward adult levels in adolescence
• Developmental psychopharmacology remains a research area of high ethical urgency Koelch et al. 2008 Meeting with the Child and their Parents 
Assent and Consent
-The right of assent to or dissent from treatment belongs to the individual child or adolescent of minor age.
-The practitioner shall, whenever possible, obtain the assent of the minor and must obtain the consent of the legal guardian -Assent from the child is recommended by the American Academy of Pediatrics
Ethics and Developmental Issues
• Most agree that preschoolers cannot give assent due to their egocentric, pre-logical and magical thinking • School children (7-12) may be more likely to engage in treatment and report effects of medication if they are engaged in the process of informed assent • Children 12 years or older possess reasoning abilities and abstract thinking similar to adults
Assent and Dissent
-When a child dissents but the guardian consents to treatment, it may be medically necessary to treat the individual minor without his or her assent -Consider the health needs of the child and the psychological ramifications of treating that child against his or her wishes. 
Ethical Considerations
• Beneficence: A genuine concern for the health, well-being, and happiness of your patients The obligation to seek out and do good for patients
Beneficence
• Our primary concerns are the welfare, functioning, and optimal development of children, these apply to individual children as well as to children as a group within society.
• Our judgments and actions should reflect these concerns, prioritizing them over familial or societal pressures. Informed Consent -Assessment of the patient's understanding of the information that you provided -Assessment of the capacity of the patient or guardian to make the necessary decision -Assurance that the patient has the freedom to choose among the medical alternatives without coercion or manipulation Olanzapine (Zyprexa)
Confidentiality
• Schizophrenia: age 13-17 start 2.5-5mg/day with dose increments 2.5-5mg over several days and target dose of 10mg/day
• Acute or mixed mania ages 13-17 start 2.5-5mg day with dose range 2.5-20mg/day Flexible dose range 400 to 800mg daily • Acute Mania 10-17 years: as above with flexible dose range 400-600mg a day Aripiprazole (Abilify)
• Schizophrenia ages 13-17 Initial dose of 2mg daily then titrate to 5mg after at least two days and then to target dose of 10mg daily after two additional days • Autism ages 6-17: 2mg/day with increase to 5mg/day, with subsequent increases to 10 or 15mg/day. Dose adjustments at intervals no less than one week
• Acute Mania 10-17 years Initial dose of 2mg daily then titrate to 5mg after at least two days and then to target dose of 10mg daily after two additional days Tablets: 2, 5, 10, 15, 20 and 30mg Oral solution: 1mg/ml and Injection 7.5mg/ml for IM Asenapine (Saphris)
• Manic or mixed episodes associated with bipolar I disorder: ages 10-17 years. • FDA's approval was based on the results of a 3-week study involving 403 pediatric patients, including 302 who received Asenapine twice a day in 2.5-mg, 5-mg, or 10-mg doses
Risperidone & Aripiprazole
• Risperidone has been the most thoroughly studied antipsychotic for treating severe irritability associated with ASD • Two large RPC studies lead to FDA approval in 2006 for treating severe irritability associated with ASD • 2009 aripiprazole became the second agent approved by the FDA for managing irritability in children 6-17 years-old with autism • FDA approval based on two multisite randomized, double-blind, placebo controlled trials Politte et al. 2014 Case Examples
• Jacob: 19-year-old with autistic spectrum disorder and comorbid bipolar disorder • Nathaniel: 12-year-old autistic spectrum disorder and comorbid psychosis • James: 17-year-old ASD and schizophrenia • Jose: 5-year-old with global developmental delay and hyperactivity Review of literature regarding Autistic Spectrum Disorder (ASD) and comorbid psychiatric illnesses Ethical considerations: Vulnerable population Autistic Spectrum Disorder (ASD)
• Autistic spectrum disorder (ASD) occurs in all racial, ethnic, and socioeconomic groups • Five times more common among boys than among girls • CDC estimates that about 1 in 68 children has been identified ASD • Broader definition of ASD and better efforts in diagnosis • A true increase in the number of people with an ASD cannot be ruled out.
Autistic Spectrum Disorder and Comorbid Psychiatric Illnesses
• Recognition and treatment of psychiatric illness in those with developmental disability is often overlooked • Psychiatric symptoms may be falsely attributed to the underlying developmental disorder and simply Literature on ASD and Comorbid Psychotic Disorders
• Wachtel & Shorter, 2013 concluded that there may be a "vulnerability punch" giving those with ASD at baseline with higher risk of comorbid psychiatric illness including psychosis • Another review found "schizophrenic-type illness" in 10% of patients with ASD, leading to the proposal that ASD might be a "vulnerability factor" for the development of psychosis Nylander at al. 2008 Jose Exam
• Highly irritable, arching spine and screaming as his mother is holding him • I asked that she let him stand at which point he ran head-first into a wall, turned around and ran head-first into the opposite wall • He then threw himself onto the floor and was banging his head and screaming • Mother appeared exhausted but deeply committed to caring for her child • Started Risperidone Solution 0.25mg daily and return in 2 weeks, sooner PRN Jose's Progress
• Risperidone titrated to 0.25mg bid but not tolerated due to drooling • Dose increased to 0.125mg in the am and 0.25mg in pm • One-month later self-injury and irritability has clearly diminished • "Hyperactivity" has decreased by "60%" • Had initial experienced drooling when starting risperidone and that has ceased • Conduct in school is much better and he is sleeping well
I Did Mention Art
• Anna Freud pinpoints as a key ingredient of healing: empathy and compassion • Maimonides proclaimed: "The physician should not treat the disease but the patient who is suffering from it." • Psychiatric nurses know that empathy is gained through an understanding of the individual you're treating. An understanding, not just of their neurobiology, but of their culture, history, literature, "heroes," music, creative influences and what moves them?
